Somapacitan, a long-acting human growth hormone analog, was evaluated in growth hormone treatment-naïve, pre-pubertal pediatric patients.

Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with the highest relaxivity, in comparison to other availab ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...

Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...

First self-administered, needle-free injection system approved by Health Canada gives access to safe, painless, cost-effective, and more sustainable drug delivery for chronic illnesses Toronto, ...